Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Open-Labeled, Single-Armed Combination Treatment With Anastrozole, Fulvestrant and Abemaciclib for Hormone Receptor Positive, HER2(-) Metastatic Breast Cancer

NCT05524584 is registered in ClinicalTrials.gov with University of California, Irvine as lead sponsor.

NCT NCT05524584
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05524584 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Open-Labeled, Single-Armed Combination Treatment With Anastrozole, Fulvestrant and Abemaciclib for Hormone Receptor Positive, HER2(-) Metastatic Breast Cancer
Lead sponsor
University of California, Irvine
Phase
Phase 2
Overall status
Recruiting
Start date
August 31, 2022
Completion date
December 31, 2031
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, her2-negative breast cancer, hormone receptor-positive breast cancer, metastatic breast cancer